Furthermore, HER2‐low breast cancer was associated with a lower percentage of grade 3 tumors than the HER2‐0 group (25.4% vs. 33.6%, p < 0.001), similar to HR‐negative patients (59.5% vs. 68.7%, p = 0.001). This evidence concerns the gene ERBB2 and breast carcinoma.